慢性和系统性炎症与骨量减少和相关骨折的风险增加有关。然而,关于低度炎症与骨矿物质密度(BMD)和股骨颈强度之间的关联的研究仍然很少且不一致。这项研究旨在检查成人队列中血液炎症生物标志物与BMD和股骨颈强度之间的关系。我们回顾性分析了美国中年(MIDUS)研究中的767名参与者。炎症标志物的血液水平,包括白细胞介素-6(IL6),可溶性IL-6受体,IL-8,IL-10,TNF-α和C反应蛋白(CRP),在这些参与者中进行了测量,并确定其与BMD和股骨颈强度的关系。我们分析了这767名受试者的BMD数据,弯曲强度指数(BSI),抗压强度指数(CSI),股骨颈和炎症生物标志物的冲击强度指数(ISI)。重要的是,我们的结果表明,血液可溶性IL6受体水平和BMD之间存在强烈的负相关(每SD变化,Sβ=-0.15;P<0.001),CSI(根据SD变化,Sβ=-0.07;P=0.039),BSI(根据SD变化,Sβ=-0.07;P=0.026),和ISI(根据SD变化,Sβ=-0.12;P<0.001)在调整年龄后的股骨颈中,性别,经常抽烟,饮酒年限,BMI和定期锻炼。然而,炎症生物标志物,包括血液IL-6(根据SD变化,Sβ=0.00;P=0.893),IL-8(根据SD变化,Sβ=-0.00;P=0.950),IL-10(每次SD变化,Sβ=-0.01;P=0.854),TNF-α(每SD变化,Sβ=0.04;P=0.260)和CRP(每SD变化,Sβ=0.05;P=0.137),在相同条件下,与股骨颈的BMD没有很强的相关性。同样,炎症生物标志物(IL-6、IL-8、IL-10、TNF-α和CRP)与CSI之间的关系没有显著差异,BSI,和股骨颈的ISI.有趣的是,在伴随炎症相关的慢性疾病中,只有关节炎影响了可溶性IL-6受体以及股骨颈中的CIS(相互作用P=0.030)和SIS(相互作用P=0.050)。在这个横截面分析中,我们仅观察到血中高水平的可溶性IL-6受体与股骨颈骨密度和骨强度降低密切相关.其他炎症指标之间的独立关联,包括IL-6、IL-8、IL-10、TNF-α和CRP,在以成人为基础的队列中,BMD和股骨颈强度并不显著.
Chronic and systematic inflammation have been related to increased risks of osteopenia and related fracture. However, studies concerning the association between low-grade inflammation and the bone mineral density (BMD) and strength of the femoral neck are still few and inconsistent. This
study aimed to examine the relationships between blood inflammatory biomarkers and BMD and femoral neck strength in an adult-based cohort. We retrospectively analyzed a total of 767 participants included in the Midlife in the United States (MIDUS)
study. The blood levels of inflammatory markers, including interleukin-6 (IL6), soluble IL-6 receptor, IL-8, IL-10, TNF-α and C-reactive protein (CRP), in these participants were measured, and their associations with the BMD and strength of the femoral neck were determined. We analyzed these 767 subjects with data concerning the BMD, bending strength index (BSI), compressive strength index (CSI), and impact strength index (ISI) in the femoral neck and inflammatory biomarkers. Importantly, our results suggest that strongly negative associations exist between the blood soluble IL6 receptor levels and the BMD (per SD change, Sβ = -0.15; P < 0.001), CSI (per SD change, Sβ = -0.07; P = 0.039), BSI (per SD change, Sβ = -0.07; P = 0.026), and ISI (per SD change, Sβ = -0.12; P < 0.001) in the femoral neck after adjusting for age, gender, smoked cigarettes regularly, number of years drinking, BMI and regular exercise. However, the inflammatory biomarkers, including blood IL-6 (per SD change, Sβ = 0.00; P = 0.893), IL-8 (per SD change, Sβ = -0.00; P = 0.950), IL-10 (per SD change, Sβ = -0.01; P = 0.854), TNF-α (per SD change, Sβ = 0.04; P = 0.260) and CRP (per SD change, Sβ = 0.05; P = 0.137), were not strongly associated with the BMD in the femoral neck under the same conditions. Similarly, there was no significant difference in the relationships between the inflammatory biomarkers (IL-6, IL-8, IL-10, TNF-α and CRP) and the CSI, BSI, and ISI in the femoral neck. Interestingly, in concomitant inflammation-related chronic diseases, only arthritis affected the soluble IL-6 receptor and the CIS (interaction P = 0.030) and SIS (interaction P = 0.050) in the femoral neck. In this cross-sectional analysis, we only observed that high blood levels of soluble IL-6 receptor were strongly associated with reduced BMD and bone strength in the femoral neck. The independent associations between the other inflammatory indicators, including IL-6, IL-8, IL-10, TNF-α and CRP, and the BMD and femoral neck strength in an adult-based cohort were not significant.